Invitae (NYSE:NVTA) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Invitae (NYSE:NVTA) in a research note released on Monday. The firm issued a hold rating on the medical research company’s stock.

Invitae Stock Performance

Shares of NYSE:NVTA remained flat at $0.00 during midday trading on Monday. The stock had a trading volume of 78,208 shares, compared to its average volume of 23,716,614. The stock has a market capitalization of $53,402.00, a P/E ratio of 0.00 and a beta of 1.59. Invitae has a twelve month low of $0.02 and a twelve month high of $0.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NVTA. Vestmark Advisory Solutions Inc. purchased a new position in shares of Invitae in the 4th quarter worth $526,000. SG Americas Securities LLC increased its stake in Invitae by 90.7% during the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after acquiring an additional 43,717 shares during the last quarter. Finally, Prosperity Wealth Management Inc. purchased a new position in shares of Invitae in the 4th quarter worth about $144,000. Institutional investors and hedge funds own 61.28% of the company’s stock.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.